Innoviva, Inc. 10-Qquarter ended 2026-06-30
Positive
XACDURO and GIAPREZA growth outweighed declining GSK royalties; investment valuation losses swung GAAP earnings to a loss.
Filed 2026-08-05 16:26 ET
Key figures · Q2 FY2026 · period ended 2026-06-30
- Revenue$119.6M1YoY +19.3%QoQ +22.0%
- Operating income$50.9MYoY +4.3%QoQ +33.3%
- Net income−$83.4MYear ago $63.7MPrevious quarter $186.6M
- Total assets$1.7BYoY +27.7%QoQ −7.3%
- Total debt$258.5MYoY −42.4%QoQ +0.1%
- Shareholders' equity$1.2BYoY +72.5%QoQ −8.1%
- Tangible book value$1.0BYoY +108.6%QoQ −8.9%
Notes (1)
- Revenue: Total revenue (royalty revenue and net product sales); excludes interest and dividend income, which this company presents below operating income.
How this filing reads
- Health+0.6Cash of $570M and H1 free cash flow of $86.3M support $261M notes due 2028.
- Momentum+0.4Q2 revenue rose 19% and product sales 46%, while royalties fell 12% and operating income grew 4%.
- Outlook+0.2New launches, including NUZOLVENCE expected in H2 2026, may offset declining GSK royalties.
Executive Summary
Innoviva’s hospital-focused products drove Q2 revenue growth even as GSK respiratory royalties declined under U.S. pricing pressure. Product growth did not translate into comparable operating-income growth because product costs and commercial spending rose; the reported $83.4M Q2 net loss instead reflects large investment valuation losses. Cash generation and a $570M cash balance support launches and repurchases, but the investor case depends on sustained product growth outweighing royalty erosion without further material investment losses.
Key Financial Highlights
| Metric | Q2 2026 | H1 2026 or 6/30/2026 | Investor interpretation |
|---|---|---|---|
| Revenue | $120M, +19% Y/Y | $218M, +15% Y/Y | Product growth outweighed declining royalties. |
| Net product sales | $51.8M, +46% Y/Y | $93.1M, +42% Y/Y | Increasingly important growth driver. |
| Net royalty revenue | $56.3M, −12% Y/Y | $112M, −8% Y/Y | GSK-related income is contracting. |
| Gross profit | $90.6M, vs $83.1M | — | Margin fell as the product mix expanded. |
| Operating income | $50.9M, +4% Y/Y | $89.0M, vs $90.2M | Revenue growth yielded limited operating leverage. |
| GAAP net income (loss) | $(83.4)M, vs $63.7M income | $103M, vs $17.1M | Investment marks dominate reported earnings. |
| Total assets | — | $1.70B | Includes substantial strategic investments. |
| Stockholders’ equity | — | $1.23B | Balance-sheet capital base. |
| Tangible common equity | — | $1.05B | Equity less $17.9M of goodwill and $169M of intangible assets. |
- Revenue mix: Q2 license and other revenue was $11.5M; H1 was $12.9M, including regulatory and licensing payments that may not recur at the same pace.
- Margins and spending: Q2 gross margin fell to 75.8% from 82.9%. Selling, general and administrative expense rose to $34.6M from $26.4M as commercial activity expanded; lower R&D partly offset the increase.
- Earnings quality: Q2 included $132M of equity-method investment losses and $29.2M of equity and long-term investment losses. H1 OCF was $87.3M vs $103M of net income; $0.921M of capital expenditures put FCF at $86.3M. Noncash investment marks and changes in operating assets and liabilities complicate the earnings-to-cash comparison.
- Capital allocation: H1 repurchases totaled $51.8M for 2.37M shares, while shares outstanding fell 2.00M to 72.6M after issuance and other share changes. Stock-based compensation rose to $7.31M from $4.57M.
- Liquidity and financing: Cash was $570M. The 2028 notes had $261M principal outstanding; the $61.6M carrying value of the GIAPREZA royalty obligation carried a 26.38% current-period effective interest rate.
Business Developments
XACDURO and GIAPREZA led product growth: Q2 sales were $22.4M and $22.3M, respectively, while XERAVA declined. International XACDURO sales contributed to growth, although much of the increase came from interim supply to Zai Lab billed at cost; that volume should not be read as equivalent to higher-margin commercial sales. GSK royalty declines, which management primarily attributed to lower U.S. sales amid pricing pressure, make the product portfolio more important to future growth.
Management is broadening that portfolio through ZEVTERA, launched in the United States in July 2025, and NUZOLVENCE, approved in December 2025 and expected to become available in H2 2026. It also licensed XACDURO rights in additional international territories and launched Nortiva Bio to develop a long-acting oral drug-delivery platform. These initiatives diversify potential revenue sources but require commercial execution and investment. Separately, the ISP Fund wind-down returned $47.5M of cash in H1, while Innoviva continued funding portfolio companies.
Risk Assessment
- Investment valuation: Strategic healthcare investments totaled $670M, including $458M associated with Armata; $316M of assets measured at fair value were Level 3. Market moves and model assumptions can overwhelm operating results.
- Royalty dependence: GSK controls commercialization of medicines generating Innoviva’s respiratory royalties, limiting its ability to counter U.S. pricing pressure or partner-sales declines.
- Product concentration and execution: Three specialty distributors represented 67% of Q2 product sales and 73% of product-sale receivables; distributor, supply or launch setbacks could interrupt the growth offset to royalties.
- Portfolio funding: Innoviva owned 67.5% of Armata and extended it a $25.0M loan at 14%; further portfolio commitments could compete with repurchases and product investment for cash.
- Financing cost: The GIAPREZA royalty obligation’s high effective interest rate burdens product economics, while the notes’ March 2028 maturity creates a future refinancing decision.
This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: FY2025 10-K.
Strategic Outlook and Investor Actionables
The near-term thesis is a shift toward specialty-product sales and new launches, financed by existing cash and royalties. The test is whether product growth produces better margins and cash flow while GSK royalties decline and investment marks remain volatile.
- Product economics: Track XACDURO, GIAPREZA and new-launch sales alongside gross margin; growth without margin stabilization would weaken the operating case.
- Royalty trajectory: Track net GSK royalties and their rate of decline; continued erosion raises the growth required from products.
- Cash and valuation: Compare OCF and net share-count reduction with repurchases, while monitoring Armata and other investment marks; these reveal whether operating progress is reaching shareholders.
Figures are computed from the filing's XBRL data; the summary and scores are written by an AI model reading the filing.
Model 005 · prompt 9e47f58d3c